We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NxStage (NXTM) Jumps 28% on $2 Billion Acquisition by FMS
Read MoreHide Full Article
German dialysis provider Fresenius Medical Care (FMS - Free Report) announced that it will acquire U.S. home dialysis device maker NxStage Medical, Inc. for $2 billion. In reaction to this news, shares of NxStage skyrocketed 28% in morning trading on Monday.
Fresenius Medical Care will acquire all outstanding shares of NxStage for $30.00 per share, in cash. The merger has already been approved by NxStage’s board.
The German company is the world’s largest provider of products and services for individuals with renal diseases. It currently operates 3,690 dialysis clinics globally for 315,305 patients. The merger will allow Fresenius Medical Care to strengthen its vertically integrated business.
“The acquisition supports our 2020 strategic initiative of driving growth in the core business with innovation, better clinical outcomes through Care Condition and improving the patient experience,” said Rice Powell, Chairman and CEO of Fresenius Medical Care.
“The combination of Fresenius Medical Care’s industry leadership with NxStage’s innovative products and employees has the potential to significantly advance the standard of care for patients around the world,” said Jeff Burbank, Founder and CEO of NxStage.
“Fresenius Medical Care would like us to continue doing what we do best, and a lot more of it,” said Burbank. “I strongly believe our opportunities would be greater working together for the benefit of patients, customers and shareholders.”
The merger is subject to approval by NxStage stockholders and other regulatory approvals. Fresenius Medical Care expects the deal to close in 2018.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NxStage (NXTM) Jumps 28% on $2 Billion Acquisition by FMS
German dialysis provider Fresenius Medical Care (FMS - Free Report) announced that it will acquire U.S. home dialysis device maker NxStage Medical, Inc. for $2 billion. In reaction to this news, shares of NxStage skyrocketed 28% in morning trading on Monday.
Fresenius Medical Care will acquire all outstanding shares of NxStage for $30.00 per share, in cash. The merger has already been approved by NxStage’s board.
The German company is the world’s largest provider of products and services for individuals with renal diseases. It currently operates 3,690 dialysis clinics globally for 315,305 patients. The merger will allow Fresenius Medical Care to strengthen its vertically integrated business.
“The acquisition supports our 2020 strategic initiative of driving growth in the core business with innovation, better clinical outcomes through Care Condition and improving the patient experience,” said Rice Powell, Chairman and CEO of Fresenius Medical Care.
“The combination of Fresenius Medical Care’s industry leadership with NxStage’s innovative products and employees has the potential to significantly advance the standard of care for patients around the world,” said Jeff Burbank, Founder and CEO of NxStage.
“Fresenius Medical Care would like us to continue doing what we do best, and a lot more of it,” said Burbank. “I strongly believe our opportunities would be greater working together for the benefit of patients, customers and shareholders.”
The merger is subject to approval by NxStage stockholders and other regulatory approvals. Fresenius Medical Care expects the deal to close in 2018.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>